vs

Side-by-side financial comparison of Core Laboratories Inc. (CLB) and CRA INTERNATIONAL, INC. (CRAI). Click either name above to swap in a different company.

CRA INTERNATIONAL, INC. is the larger business by last-quarter revenue ($197.0M vs $121.8M, roughly 1.6× Core Laboratories Inc.). CRA INTERNATIONAL, INC. runs the higher net margin — 6.7% vs 4.2%, a 2.5% gap on every dollar of revenue. On growth, CRA INTERNATIONAL, INC. posted the faster year-over-year revenue change (11.6% vs -1.4%). Over the past eight quarters, CRA INTERNATIONAL, INC.'s revenue compounded faster (7.1% CAGR vs -3.4%).

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

CRA International, Inc. is a global consulting firm headquartered in Boston. The firm provides expert testimony and litigation support, strategic advice, and analysis to law firms, corporations, accounting firms, and governments.

CLB vs CRAI — Head-to-Head

Bigger by revenue
CRAI
CRAI
1.6× larger
CRAI
$197.0M
$121.8M
CLB
Growing faster (revenue YoY)
CRAI
CRAI
+13.1% gap
CRAI
11.6%
-1.4%
CLB
Higher net margin
CRAI
CRAI
2.5% more per $
CRAI
6.7%
4.2%
CLB
Faster 2-yr revenue CAGR
CRAI
CRAI
Annualised
CRAI
7.1%
-3.4%
CLB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLB
CLB
CRAI
CRAI
Revenue
$121.8M
$197.0M
Net Profit
$5.1M
$13.2M
Gross Margin
Operating Margin
1.5%
10.5%
Net Margin
4.2%
6.7%
Revenue YoY
-1.4%
11.6%
Net Profit YoY
-12.0%
EPS (diluted)
$0.11
$1.99

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLB
CLB
CRAI
CRAI
Q1 26
$121.8M
Q4 25
$138.3M
$197.0M
Q3 25
$134.5M
$185.9M
Q2 25
$130.2M
$186.9M
Q1 25
$123.6M
$181.9M
Q4 24
$129.2M
$176.4M
Q3 24
$134.4M
$167.7M
Q2 24
$130.6M
$171.4M
Net Profit
CLB
CLB
CRAI
CRAI
Q1 26
$5.1M
Q4 25
$4.9M
$13.2M
Q3 25
$14.2M
$11.5M
Q2 25
$10.6M
$12.1M
Q1 25
$-154.0K
$18.0M
Q4 24
$7.4M
$15.0M
Q3 24
$11.7M
$11.4M
Q2 24
$9.0M
$6.5M
Gross Margin
CLB
CLB
CRAI
CRAI
Q1 26
Q4 25
20.8%
Q3 25
22.0%
Q2 25
20.3%
Q1 25
19.5%
Q4 24
17.8%
Q3 24
20.5%
Q2 24
21.2%
Operating Margin
CLB
CLB
CRAI
CRAI
Q1 26
1.5%
Q4 25
11.5%
10.5%
Q3 25
15.6%
9.3%
Q2 25
11.7%
10.6%
Q1 25
3.6%
14.0%
Q4 24
11.0%
12.2%
Q3 24
14.7%
11.0%
Q2 24
12.3%
6.6%
Net Margin
CLB
CLB
CRAI
CRAI
Q1 26
4.2%
Q4 25
3.6%
6.7%
Q3 25
10.6%
6.2%
Q2 25
8.2%
6.5%
Q1 25
-0.1%
9.9%
Q4 24
5.7%
8.5%
Q3 24
8.7%
6.8%
Q2 24
6.9%
3.8%
EPS (diluted)
CLB
CLB
CRAI
CRAI
Q1 26
$0.11
Q4 25
$0.11
$1.99
Q3 25
$0.30
Q2 25
$0.22
Q1 25
$0.00
Q4 24
$0.15
Q3 24
$0.25
Q2 24
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLB
CLB
CRAI
CRAI
Cash + ST InvestmentsLiquidity on hand
$22.8M
$18.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$275.1M
$213.6M
Total Assets
$587.7M
$628.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLB
CLB
CRAI
CRAI
Q1 26
$22.8M
Q4 25
$22.7M
$18.2M
Q3 25
$25.6M
$22.5M
Q2 25
$31.2M
$19.4M
Q1 25
$22.1M
$25.6M
Q4 24
$19.2M
$26.7M
Q3 24
$21.5M
$24.5M
Q2 24
$17.7M
$24.6M
Total Debt
CLB
CLB
CRAI
CRAI
Q1 26
Q4 25
$110.3M
Q3 25
$114.1M
Q2 25
$124.6M
Q1 25
$124.4M
Q4 24
$126.1M
Q3 24
$139.9M
Q2 24
$147.6M
Stockholders' Equity
CLB
CLB
CRAI
CRAI
Q1 26
$275.1M
Q4 25
$266.0M
$213.6M
Q3 25
$271.3M
$201.7M
Q2 25
$261.3M
$197.0M
Q1 25
$253.4M
$227.3M
Q4 24
$246.6M
$212.1M
Q3 24
$250.7M
$204.5M
Q2 24
$240.3M
$191.7M
Total Assets
CLB
CLB
CRAI
CRAI
Q1 26
$587.7M
Q4 25
$584.0M
$628.9M
Q3 25
$591.4M
$629.0M
Q2 25
$602.1M
$606.8M
Q1 25
$591.5M
$590.4M
Q4 24
$585.1M
$571.4M
Q3 24
$600.5M
$582.3M
Q2 24
$597.8M
$546.0M
Debt / Equity
CLB
CLB
CRAI
CRAI
Q1 26
Q4 25
0.41×
Q3 25
0.42×
Q2 25
0.48×
Q1 25
0.49×
Q4 24
0.51×
Q3 24
0.56×
Q2 24
0.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLB
CLB
CRAI
CRAI
Operating Cash FlowLast quarter
$4.0M
$22.4M
Free Cash FlowOCF − Capex
$517.0K
FCF MarginFCF / Revenue
0.4%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.77×
1.70×
TTM Free Cash FlowTrailing 4 quarters
$22.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLB
CLB
CRAI
CRAI
Q1 26
$4.0M
Q4 25
$7.9M
$22.4M
Q3 25
$8.5M
$36.5M
Q2 25
$13.9M
$5.9M
Q1 25
$6.7M
$-80.0M
Q4 24
$20.6M
$79.4M
Q3 24
$13.1M
$31.6M
Q2 24
$17.1M
$1.8M
Free Cash Flow
CLB
CLB
CRAI
CRAI
Q1 26
$517.0K
Q4 25
$5.0M
Q3 25
$6.5M
$35.9M
Q2 25
$10.4M
$4.7M
Q1 25
$3.9M
$-81.0M
Q4 24
$17.4M
$68.8M
Q3 24
$10.4M
$28.6M
Q2 24
$14.3M
$-509.0K
FCF Margin
CLB
CLB
CRAI
CRAI
Q1 26
0.4%
Q4 25
3.6%
Q3 25
4.8%
19.3%
Q2 25
8.0%
2.5%
Q1 25
3.1%
-44.5%
Q4 24
13.4%
39.0%
Q3 24
7.7%
17.0%
Q2 24
10.9%
-0.3%
Capex Intensity
CLB
CLB
CRAI
CRAI
Q1 26
Q4 25
2.1%
Q3 25
1.5%
0.3%
Q2 25
2.7%
0.6%
Q1 25
2.3%
0.5%
Q4 24
2.5%
6.0%
Q3 24
2.0%
1.8%
Q2 24
2.2%
1.4%
Cash Conversion
CLB
CLB
CRAI
CRAI
Q1 26
0.77×
Q4 25
1.61×
1.70×
Q3 25
0.60×
3.19×
Q2 25
1.31×
0.48×
Q1 25
-4.44×
Q4 24
2.78×
5.30×
Q3 24
1.12×
2.76×
Q2 24
1.90×
0.28×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons